8-K: Revelation Biosciences Reports Financial Results for Q4 and Full Year 2024, Highlights Clinical Progress

Revelation Biosciences announced its financial results for the three and twelve months ended December 31, 2024, and provided updates on its clinical programs.

Summary

• Revelation Biosciences reported its financial results for the three and twelve months ended December 31, 2024.
• The company had $6.5 million in cash and cash equivalents as of December 31, 2024, compared to $12.0 million as of December 31, 2023.
• The decrease in cash was primarily due to operating activities, including payments related to the LifeSci Capital LLC judgment and SPAC IPO bankers.
• Net cash used for operating activities for the year ended December 31, 2024, was $18.3 million, compared to $7.3 million for the same period in 2023.
• The net loss for the three months ended December 31, 2024, was $1.7 million, or $4.98 per share, compared to a net loss of $2.2 million, or $133.64 per share, for the same period in 2023.
• The net loss for the twelve months ended December 31, 2024, was $15.0 million, or $87.68 per share, compared to a net loss of $0.1 million, or $8.44 per share, for the same period in 2023.
• The company believes its current cash and cash equivalents are sufficient to fund operations into 2025.
• Revelation is focused on rebalancing inflammation to optimize health, with its lead candidate Gemini being developed for multiple indications.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While the company is progressing with its clinical trials and has sufficient cash to operate into 2025, the increased net loss and cash burn are concerning.

Positives

• Revelation Biosciences has $6.5 million in cash and cash equivalents as of December 31, 2024.
• The company received $3.7 million from warrant exercises in December 2024.
• The company believes its current cash and cash equivalents are sufficient to fund operations into 2025.
• The company announced dosing of the first patient in the PRIME Phase 1b Clinical Study of Gemini in CKD patients.
• The FDA accepted the Gemini IND.

Negatives

• Revelation Biosciences experienced a significant increase in net loss for the year ended December 31, 2024, at $15.0 million compared to $0.1 million in 2023.
• Cash and cash equivalents decreased from $12.0 million as of December 31, 2023, to $6.5 million as of December 31, 2024.
• Net cash used for operating activities increased to $18.3 million for the year ended December 31, 2024, compared to $7.3 million in 2023.

Risks

• The company's ability to meet its financial and strategic goals is subject to competition and other economic, business, and/or competitive factors.
• The successful development of Revelation's product candidates is subject to risks.
• The company may not fully enroll its clinical studies or enrollment may take longer than expected.
• Adverse safety events and/or unexpected concerns may arise from data or analysis from clinical studies.
• Changes in applicable laws or regulations could adversely affect the company.
• The company's ability to maintain the listing of its securities on NASDAQ is subject to risk.
• The company's forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause actual results to be materially different from those anticipated.

Future Outlook

Revelation believes that its current cash and cash equivalents are sufficient to fund operations into 2025, and anticipates completion of enrollment and topline data from the Phase 1b PRIME clinical study mid-year.

Management Comments

• We made significant progress at the end of last year and hope to continue that pace in 2025, said James Rolke, Chief Executive Officer of Revelation.
• Now that the Phase 1b PRIME clinical study is up and running we anticipate the completion of enrollment and more importantly topline data mid-year.

Industry Context

Revelation Biosciences is a clinical-stage life sciences company focused on harnessing the power of trained immunity for the prevention and treatment of disease. The company's focus on rebalancing inflammation to optimize health aligns with the growing interest in immunomodulatory therapies in the biotechnology industry. Competitors in this space include companies developing therapies for inflammatory and autoimmune diseases, as well as companies focused on kidney disease and post-surgical infections.

Comparison to Industry Standards

• It is difficult to compare Revelation Biosciences directly to industry standards without more specific information on comparable companies and projects.
• However, the company's cash runway into 2025 is a key metric to consider in comparison to other clinical-stage biotech companies.
• The increase in net loss and cash used for operating activities should be evaluated in the context of the company's clinical development programs and overall strategy.
• Companies like Chinook Therapeutics (now Novartis) and Vera Therapeutics, which are focused on kidney diseases, could be considered peers for the GEMINI-CKD program.
• For the GEMINI-PSI program, companies developing anti-infective therapies or strategies to prevent post-surgical infections would be relevant comparators.

Stakeholder Impact

• Shareholders may be concerned about the increased net loss and cash burn.
• Employees may be affected by the company's ability to maintain operations and continue development programs.
• Patients may benefit from the successful development of Gemini for various indications.
• Suppliers and creditors may be affected by the company's financial performance and ability to meet its obligations.

Next Steps

• Complete enrollment and obtain topline data from the Phase 1b PRIME clinical study of Gemini in CKD patients by mid-year 2025.
• Continue development of Gemini for multiple indications, including GEMINI-AKI, GEMINI-PSI, and GEMINI-CKD programs.

Key Dates

Keywords

Revelation Biosciences, Financial Results, Gemini, Clinical Study, CKD, Phase 1b, Cash Position, Net Loss, Warrants, FDA, REVB, REVBW